Targeting the APP-Mint2 Protein-Protein Interaction with a Peptide-Based Inhibitor Reduces Amyloid-β Formation

Area of Science:

• Neuroscience
• Molecular Biology
• Drug Discovery

Background:

• Alzheimer's disease (AD) urgently requires new treatments to manage symptoms and halt progression.
• Amyloid-beta (Aβ) peptide accumulation, from amyloid precursor protein (APP) cleavage, characterizes AD.
• Mint2 protein's role in Aβ generation has been debated, with conflicting reports on its effect.

Purpose of the Study:

• To clarify the role of Mint2 in amyloid precursor protein (APP) processing and Aβ generation.
• To investigate the protein-protein interaction (PPI) between APP and Mint2.
• To develop novel therapeutic strategies targeting the APP-Mint2 interaction.

Main Methods:

• Detailed analysis of the APP-Mint2 protein-protein interaction (PPI) through backbone H-bond and side-chain interaction probing.
• Development of a stable, high-affinity peptide inhibitor for the APP-Mint2 interaction.
• Utilizing a neuronal in vitro model of Alzheimer's disease to assess Aβ levels.

Main Results:

• The study elucidated the specific interactions between APP and Mint2.
• A cell-permeable peptide inhibitor targeting the APP-Mint2 PPI significantly reduced Aβ42 levels.
• An APP binding-deficient Mint2 variant also led to decreased Aβ42 levels in vitro.

Conclusions:

• Mint2 plays a facilitative role in the formation of pathogenic Aβ peptides.
• Targeting the Mint2 protein, via genetic or pharmacological means, presents a viable therapeutic avenue for reducing Aβ levels in Alzheimer's disease.
• This research provides a foundation for developing novel Alzheimer's disease therapeutics.